Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
CTNM Stock Chart & Stats
$12.52
-$0.71(-5.12%)
At close: 4:00 PM EST
$12.52
-$0.71(-5.12%)
Day’s Range― - ―
52-Week Range$3.35 - $15.25
Previous CloseN/A
Volume54.82K
Average Volume (3M)170.88K
Market Cap
$306.67M
Enterprise Value-$66.93M
Total Cash (Recent Filing)$182.41M
Total Debt (Recent Filing)$5.49M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Mar 05, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding23,099,173
10 Day Avg. Volume105,448
30 Day Avg. Volume170,880
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-8.50
Enterprise Value/Market Cap-0.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit418.29
Enterprise Value/Ebitda1.09
Forecast
1Y Price Target
$19.80Price Target Upside58.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PIPE-791 EfficacyPIPE-791 succeeded in showing high LPA1 receptor occupancy in the brain tissue of studied subjects.
Potential Of PIPE-791PIPE-791 has best-in-class potential, making the IPF opportunity undervalued.
Strategic Financial ManagementA strategic decision to defer certain clinical studies has extended the company's projected financial runway through 2028.
Bears Say
Challenges In Lung Receptor OccupancyLung receptor occupancy could not be established, likely due to low receptor expression and limitations with imaging lung vs. brain.
Market Reaction To Trial ResultsContineum shares are trading down modestly (~14%) after hours, following an announcement that the Phase II VISTA trial of PIPE-307, an M1 muscarinic receptor antagonist licensed by Johnson & Johnson, as an adjunctive treatment in relapsing-remitting multiple sclerosis did not meet its prespecified primary or secondary efficacy endpoints.
PIPE-307 Trial ResultsCTNM disclosed that the ph2 VISTA trial of PIPE-307 (M1R antagonist) in RRMS did not meet either its prespecified primary or secondary endpoints.
Contineum Therapeutics, Inc. Class A News
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $3.35 and its highest was $15.25 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Contineum Therapeutics, Inc. Class A’s market cap is $306.67M.
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Mar 05, 2026 which is in 83 days.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Oct 30, 2025. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.034.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -0.44.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 23,099,173 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 4.459%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Currently, no hedge funds are holding shares in CTNM
Contineum Therapeutics, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.80 (58.15% Upside)
$19.80 (58.15% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.5%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.24%
12-Months-Change
Fundamentals
Return on Equity
-30.40%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc. Class A (CTNM) is a biotechnology company focused on the development and commercialization of innovative therapies aimed at treating rare and complex diseases. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on research and development of novel drug candidates. Contineum Therapeutics leverages cutting-edge technology and advanced scientific methods to address unmet medical needs, striving to deliver transformative treatments to patients worldwide.
CTNM Stock 12 Month Forecast
Average Price Target
$19.80
▲(58.15% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Alpha Tau Medical Ltd
―
Immuneering
―
enGene Holdings
―
Ownership Overview
0.80%
Insiders
9.31% Mutual Funds
45.58% Other Institutional Investors
40.12% Public Companies and
Individual Investors